<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7786">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888654</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000641168</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2007-128</secondary_id>
    <nct_id>NCT00888654</nct_id>
  </id_info>
  <brief_title>Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy</brief_title>
  <official_title>Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The use of diindolylmethane, a substance found in cruciferous vegetables, may
      slow the growth of tumor cells.

      PURPOSE: This phase II trial is studying how well diindolylmethane works in treating
      patients with stage I or stage II prostate cancer undergoing radical prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To measure the level of diindolylmethane in prostate tissue after treatment with oral
           microencapsulated diindolylmethane (B-DIM) in patients with stage I or II
           adenocarcinoma of the prostate undergoing radical prostatectomy.

      Secondary

        -  To measure serum biomarkers (e.g., total PSA, serum testosterone, and diindolylmethane
           levels) pre- and post-treatment with B-DIM.

        -  To measure tissue biomarkers (e.g., androgen receptor, NF-κB, and PSA) pre- and
           post-treatment with B-DIM.

      OUTLINE: This is a multicenter study.

      Patients receive oral microencapsulated diindolylmethane (B-DIM) twice daily for 14-72 days
      in the absence of disease progression or unacceptable toxicity. Patients then undergo
      radical prostatectomy 1 day after the last dose of B-DIM.

      Patients undergo blood and tissue sample collection for correlative laboratory studies.
      Blood samples are analyzed for serum PSA, testosterone, and diindolylmethane levels by high
      performance liquid chromatography and tandem mass spectrometry (LC-MS/MS). Tissue samples
      are analyzed for diindolylmethane concentration by LC-MS/MS and for androgen receptor,
      activated NF-κB (p65 antibody), and PSA expression by IHC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Level of Diindolylmethane in Prostate Tissue After Treatment</measure>
    <time_frame>Within the first 24 months after radical prostatectomy.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of PSA, Testosterone,DIM Level and Diindolylmethane</measure>
    <time_frame>Pre and post radical prostatectomy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Androgen Receptor, NF-kB, and PSA in Prostate Tissue</measure>
    <time_frame>Pre and post radical prostatectomy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>B-Dim, Radical Prosatectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B-Dim</intervention_name>
    <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)</description>
    <arm_group_label>B-Dim, Radical Prosatectomy</arm_group_label>
    <other_name>3,3'-Diindolylmethane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Prosatectomy</intervention_name>
    <arm_group_label>B-Dim, Radical Prosatectomy</arm_group_label>
    <other_name>therapeutic conventional surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

               -  Stage I or II (T1-T2 a, b, or c) disease

               -  Disease confined to the prostate by clinical judgment of the surgeon

          -  Deemed an appropriate candidate for surgery by clinical judgment of the surgeon

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 8.0 g/dL

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and/or ALT ≤ 2.5 times ULN if alkaline phosphatase normal OR alkaline phosphatase
             ≤ 4 times ULN if AST and/or ALT normal

          -  Serum creatinine ≤ 2.0 mg/dL

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to oral microencapsulated diindolylmethane

          -  No concurrent uncontrolled illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Symptomatic congestive hart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness or social situation that would limit compliance with study
                  requirements

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy, hormonal therapy, brachytherapy, cryotherapy, external beam
             radiotherapy, or other therapy for prostate cancer

          -  No concurrent micronutrient supplements or dietary soy products

          -  No concurrent systemic therapy for any other cancer

          -  No concurrent p450 inducers or inhibitors (e.g., carbamazepine, clarithromycin,
             fluconazole, fosphenytoin, itraconazole, ketoconazole, phenobarbital, phenytoin,
             rifabutin, or rifampin)

          -  No concurrent finasteride or dutasteride

          -  No other concurrent investigational or commercial agents or therapies for the
             malignancy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth I. Heath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 23, 2015</lastchanged_date>
  <firstreceived_date>April 24, 2009</firstreceived_date>
  <firstreceived_results_date>March 23, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Elisabeth Heath</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>B-Dim, Radical Prosatectomy</title>
          <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy
B-Dim: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prosatectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Problems swallowing oral meds.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not enough oral meds before surgery</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery aborted</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inelig. due to contraindication of med</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in surg date</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Stopped meds due to headaches</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B-Dim, Radical Prosatectomy</title>
          <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy
B-Dim: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prosatectomy</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="58" lower_limit="20" upper_limit="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Level of Diindolylmethane in Prostate Tissue After Treatment</title>
        <time_frame>Within the first 24 months after radical prostatectomy.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients that were eligible, evaluable, and compliant</population>
        <group_list>
          <group group_id="O1">
            <title>B-Dim, Radical Prosatectomy</title>
            <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy
B-Dim: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prosatectomy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Level of Diindolylmethane in Prostate Tissue After Treatment</title>
            <units>ng/g</units>
            <param>Mean</param>
            <dispersion>90% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14.2" lower_limit="10.6" upper_limit="17.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of PSA, Testosterone,DIM Level and Diindolylmethane</title>
        <time_frame>Pre and post radical prostatectomy</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Androgen Receptor, NF-kB, and PSA in Prostate Tissue</title>
        <time_frame>Pre and post radical prostatectomy</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>B-Dim, Radical Prosatectomy</title>
          <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy
B-Dim: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prosatectomy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no significant limitations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elisabeth Heath, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-576-8715</phone>
      <email>heathe@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
